Karuna Therapeutics Inc

-1.00 (-0.88%)
Regulatory, Earnings Announcements

Karuna Therapeutics Announces Results From Phase 1B Trial Evaluating The Safety And Tolerability Of Karxt In Healthy Elderly Volunteers

Published: 06/23/2021 10:41 GMT
Karuna Therapeutics Inc (KRTX) - Karuna Therapeutics Announces Results From Phase 1b Trial Evaluating the Safety and Tolerability of Karxt in Healthy Elderly Volunteers.
Karuna Therapeutics - Company to Initiate a Phase 2 Trial Evaluating Karxt in Dementia-related Psychosis in First Half of 2022.
Karuna Therapeutics - Majority of Healthy Elderly Volunteers in Phase 1b Trial Were Titrated to Xanomeline Doses of 150 to 200 Mg When Dosed With Karxt.
Karuna Therapeutics - Safety and Tolerability Profile in Phase 1b Trial in Healthy Elderly Volunteers Consistent With Prior Trials of Karxt.
Karuna Therapeutics - Treatment-related Adverse Events Similar to Those Seen in Prior Trials of Karxt & Majority (>80%) Were Rated Mild in Severity.
Karuna Therapeutics Inc - One Serious Ae of Urinary Retention Was Reported in Cohort 1.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$1.35

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.55

More details on our Analysts Page.